Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2023 First Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there
are no false representations, misleading statements or material omissions contained in
this announcement and accept legal responsibility for the truthfulness, accuracy and
completeness of the contents hereof.
IMPORTANT NOTICE:
The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this
quarterly report, and that there are no false representations, misleading statements or material
omissions contained herein, and severally and jointly accept legal responsibility.
The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant the
truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
Whether the first quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
The Reporting Period
Item YoY change (%)
(From January to March)
Revenues 4,559,049,786.82 -2.11
Net profit attributable to shareholders
462,746,183.03 0.48
of the listed company
Net profit attributable to shareholders
of the listed company after deduction 446,772,473.94 -2.28
of extraordinary gains and losses
Net cash flow from operating activities 248,084,750.71 -71.55
Basic earnings per share (RMB/share) 0.2404 -0.31
Diluted earnings per share
0.2398 -0.48
(RMB/share)
Weighted average return on net assets
3.49 Decreased by 0.35 percentage points
(%)
1 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Change as at the
end of the
As at the end of the As at the end of the Reporting Period
Reporting Period previous year as compared to
the end of the
previous year(%)
Total assets 36,193,051,015.06 35,729,253,651.41 1.30
Owner's equity attributable to
13,365,070,332.08 13,121,820,410.55 1.85
shareholders of the listed company
Notes: From January to March 2023, the Company realized revenues of RMB4,559 million, representing a YoY
decrease of 2.11%. Chemical pharmaceuticals realized revenues of RMB2,250 million, representing a YoY
decrease of 16.09%, among which, RMB509 million were from respiratory formulation products, representing
a YoY increase of 41.18%; RMB793 million were from gastroenterology products, representing a YoY
decrease of 25.23%; RMB577 million were from gonadotropic hormones, representing a YoY decrease of
21.60%; RMB199 million were from anti-infection products, representing a YoY decrease of 43.29%;and
RMB122 million were from psychiatry products, representing a YoY decrease of 8.25%. APIs and
intermediates products realized revenues of RMB1,454 million, representing a YoY increase of 3.44%.
Traditional Chinese Medicine products realized revenues of RMB567 million, representing a YoY increase of
100.68%. Biological products realized revenues of RMB62 million, representing a YoY increase of 12.22%.
Diagnostic reagents and equipment products realized revenues of RMB147 million from, representing a YoY
decrease of 9.54%. Health care products realized revenues of RMB40 million, representing a YoY increase of
46.99%.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
For the
Item Explanation
Reporting Period
Government grants recognized in profit or loss for the current
period (excluding government grants closely related to the Government grants through
ordinary operating business of the Company and are entitled in 51,488,223.81 the profits and losses for the
fixed amount or quantity continuously according to the Period
applicable national polices and standards)
Gains and losses on fair value changes incurred from financial Gains or losses arising from
assets held for trading, derivative financial assets, financial changes in fair value of
liabilities held for trading and derivative financial liabilities, and financial assets/liabilities
investment income on disposal of financial assets held for held for trading, and
-18,242,051.06
trading, derivative financial assets, financial liabilities held for investment gains from
trading, derivative financial liabilities and other debt holding and disposal of
investments, except for effective hedging activities related to the financial assets/liabilities
ordinary operating business of the Company held for trading
Other non-operating income
Other non-operating income and expenses excluding the above
-2,822,249.38 and expenses excluding the
items
above items
Effect of the above items on
Less: Effect of income tax 7,100,276.22
income tax
The portion of the above
Effect of minority equity (after tax) 7,349,938.06 items to which minority
shareholders are entitled
Total 15,973,709.09
2 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Explanations for classifying items of extraordinary gains and losses defined in the Explanatory
Announcement No. 1 for Public Company Information Disclosures –Extraordinary Gains or Losses as
items of recurring gains or losses.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
√Applicable □N/A
Item Change (%) Explanation
Mainly due to the increase in procurement
Net cash flow from expenditure of raw materials and a decrease of
-71.55
operating activities cash collections of sales revenue during the
Reporting Period.
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons
Thereof
Unit: Yuan Currency: RMB
Change in
31 December
Balance Sheet 31 March 2023 proportion Main Reason
2022
（%）
Mainly due to changes in exchange
Financial liabilities
4,759,250.98 755,634.43 529.84 rates forward foreign exchange
held for trading
contracts.
Mainly because part of the contract
payments received in advance in the
Contract liabilities 118,380,947.47 292,977,730.74 -59.59 Period which met the conditions for
revenue recognition were
recognized as revenues.
Mainly due to the payment of the
Employee benefits
361,917,343.05 573,010,571.46 -36.84 year end performance bonus for the
payable
previous year.
Mainly due to increase of
Treasury shares 717,135,581.08 347,176,561.29 106.56 repurchase of shares during the
Reporting Period.
Other Mainly due to changes in the fair
comprehensive -42,580,905.41 4,704,473.53 -1005.12 value of other equity instrument
income investments.
Change in
Statement of January to January to
proportion Main Reason
Income March 2023 March 2022
（%）
Mainly due to an increase of
Financial expenses -15,861,425.43 -30,519,305.67 N/A financial expenses as a result of
exchange losses.
Mainly due to the receipt of bonus
Income from
39,625,949.95 29,176,808.52 35.81 payments during the Reporting
investments
Period.
Mainly due to fluctuations in the
Gains from changes
-27,478,190.74 -54,151,999.18 N/A market value of the securities
in fair values
investments held.
Mainly due to the receivables and
Losses of credit the increase in the expected credit
-15,459,174.59 217,773.10 -7198.75
impairment loss for the Reporting Period as
compared with the previous period.
3 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Mainly due to the provision for
Assets impairment price decline of inventories for the
1,837,691.27 -5,309,013.21 N/A
loss Reporting Period decreased as
compared with the previous period.
Mainly due to the decrease in
Non-operating income from disposal of scrap items
876,580.36 2,321,933.96 -62.25
income for the Reporting Period as
compared to the previous period.
Mainly due to the increase in
Non-operating expenditure of charitable donation
3,698,829.74 2,084,578.34 77.44
expenses for the Reporting Period as
compared with the previous period.
Change in
Cash Flow January to January to
proportion Main Reason
Statement March 2023 March 2022
（%）
Mainly due to the increase in
procurement expenditure of raw
Net cash flow from
248,084,750.71 871,904,476.98 -71.55 materials and a decrease of cash
operating activities
collections of sales revenue during
the Reporting Period.
Mainly due to the recovery of
investment amount and the
Net cash flow from decreased investment of
-71,511,309.54 -77,907,837.67 N/A
investing activities construction of new plants for the
Reporting Period as compared with
the previous period.
Mainly due to the decrease in
Net cash flow from repayment and borrowings received
-118,644,351.81 62,714,553.34 -289.18
financing activities for the Reporting Period as
compared with the previous period.
Mainly due to changes in foreign
Effect of foreign
exchange rates resulting in an
exchange rate -47,773,910.21 -12,259,201.98 N/A
increase in exchange loss from
changes on cash
foreign exchange funds held.
Mainly due to the decrease in cash
generated from ordinary operating
Net increase in cash activities and the increase in
10,155,179.14 844,451,990.66 -98.80
and cash equivalents procurement expenditure of raw
materials during the Reporting
Period.
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
Total number of holders of ordinary Total number of holders of preferred
shares as of the end of the Reporting 87,173 shares with restored voting rights as of 0
Period the end of the Reporting Period (if any)
Shareholdings of the top 10 shareholders
Number of Pledge, mark or lock-up
Nature of Number of Percentage shares held
Name of shareholder
shareholder shares held (%) with selling
restrictions Share
Number
status
4 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Shenzhen Baiyeyuan Investment Co., Domestic non-
state-owned 895,653,653 46.43 0 Pledge 95,679,725
Ltd. (深圳市百业源投资有限公司)
legal person
Hong Kong Securities Clearing Company
Unknown 110,920,501 5.75 0 Unknown
Limited
Foreign legal
Might Seasons Limited 51,931,021 2.69 0 Unknown
person
Citibank, National Association Unknown 13,780,230 0.71 0 Unknown
Huaxia Life Insurance Co., Ltd. - Own
Unknown 11,854,118 0.61 0 Unknown
fund
Domestic
He Zhong 7,800,024 0.40 0 Unknown
natural person
Agricultural Bank of China Limited - CSI
500 Exchange Traded Index Securities Unknown 7,010,694 0.36 0 Unknown
Investment Fund
Joincare Pharmaceutical Group Industry
Co., Ltd. — the Second Phase Ownership
Scheme under Medium to Long-term
Business Partner Share Ownership Others 6,275,372 0.33 0 -
Scheme (健康元药业集团股份有限公司
－中长期事业合伙人持股计划之第二
期持股计划)
Industrial Bank Co., Ltd. - Caitong Asset
Management Health Industry Hybrid Unknown 6,000,000 0.31 0 Unknown
Securities Investment Fund
108 protfolio of national social security
Unknown 5,857,721 0.30 0 Unknown
fund
Shareholdings of the top 10 shareholders without selling restrictions
Number of tradable shares held Class and number of shares
Name of shareholder
without selling restrictions Class of shares Number
Ordinary shares
Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
895,653,653 denominated in 895,653,653
投资有限公司) Renminbi
Ordinary shares
Hong Kong Securities Clearing Company Limited 110,920,501 denominated in 110,920,501
Renminbi
Ordinary shares
Might Seasons Limited 51,931,021 denominated in 51,931,021
Renminbi
Ordinary shares
Citibank, National Association 13,780,230 denominated in 13,780,230
Renminbi
Ordinary shares
Huaxia Life Insurance Co., Ltd. - Own fund 11,854,118 denominated in 11,854,118
Renminbi
Ordinary shares
He Zhong 7,800,024 denominated in 7,800,024
Renminbi
Ordinary shares
Agricultural Bank of China Limited - CSI 500 Exchange
7,010,694 denominated in 7,010,694
Traded Index Securities Investment Fund
Renminbi
Joincare Pharmaceutical Group Industry Co., Ltd. — the
Second Phase Ownership Scheme under Medium to Long- Ordinary shares
term Business Partner Share Ownership Scheme (健康元药 6,275,372 denominated in 6,275,372
业集团股份有限公司－中长期事业合伙人持股计划之第 Renminbi
二期持股计划)
Ordinary shares
Industrial Bank Co., Ltd. - Caitong Asset Management
6,000,000 denominated in 6,000,000
Health Industry Hybrid Securities Investment Fund
Renminbi
Ordinary shares
108 protfolio of national social security fund 5,857,721 denominated in 5,857,721
Renminbi
5 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
There was no connection or acting-in-concert relationship between
Description of connection or acting-in-concert relationship Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the
of the above shareholders Company, and other shareholders; whether there is connection or acting-in-
concert relationship among other shareholders is unknown.
Description of the participation of the top 10 shareholders As of the end of the Reporting Period, He Zhong, a shareholder, holds a total
and the top 10 shareholders without selling restrictions in of 7,800,024shares of the Company, including 800,000 shares held through
margin financing and securities lending and refinancing ordinary securities accounts and 7,000,024 shares held through credit
business (if any) securities accounts.
As of the end of the Reporting Period, the special repurchase account of the
Description of the special repurchase account among the Company (Special securities repurchase account of Joincare Pharmaceutical
top 10 shareholders Group Industry Co., Ltd.) owned 58,122,392 shares in total, accounting for
3.01%.
Note: Citibank, National Association is the depositary of the Company’s GDRs (Global Depository Receipts),
the corresponding underlying domestic A Shares of GDRs shall be registered under its name according to the
laws; According to the depositary’s statistics, as of the end of the Reporting Period, the Company had a total of
1,378,023 GDRs outstanding accounting for 21.59% of the total number of GDRs issued by the Company.
III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
6 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Consolidated Balance Sheet
31 March 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
Item 31 March 2023 31 December 2022
Current assets:
Monetary funds 14,458,474,995.37 14,808,488,110.96
Financial assets held for trading 85,646,883.17 109,015,664.98
Notes receivable 2,202,720,144.84 1,959,985,016.85
Accounts receivable 3,259,431,777.79 3,103,758,850.15
Receivables financing
Prepayments 457,539,057.82 364,265,142.57
Other receivables 56,254,117.17 52,535,740.14
In which: Interests receivable
Dividends receivable
Inventories 2,790,598,613.23 2,561,869,999.57
Contract assets
Assets Held-for-sale
Non-current assets due within one year 54,581,111.11 54,048,611.11
Other current assets 182,329,092.88 163,539,900.32
Total current assets 23,547,575,793.38 23,177,507,036.65
Non-current assets:
Debt investment
Other debt investment
Long-term receivables
Long-term equity investment 1,432,562,509.67 1,419,882,594.59
Other equity instrument investments 1,149,287,217.20 1,193,958,879.05
Other non-current financial assets
Investment properties 6,191,475.43 6,191,475.43
Fixed assets 5,230,295,232.48 5,265,200,110.91
Construction in progress 909,461,674.66 811,300,068.96
Productive biological assets
Oil and gas assets
Right-of-use assets 40,694,040.95 41,843,133.97
Intangible assets 832,112,818.49 802,115,125.75
Development expenditures 300,157,334.73 428,284,884.17
Goodwill 636,339,503.82 614,468,698.73
Long-term deferred expenses 290,036,796.09 277,867,716.95
Deferred income tax assets 506,141,586.79 533,861,743.26
Other non-current assets 1,312,195,031.38 1,156,772,182.99
Total non-current assets 12,645,475,221.68 12,551,746,614.76
Total assets 36,193,051,015.06 35,729,253,651.41
Current liabilities:
Short-term loans 2,099,069,713.00 2,126,050,615.06
Financial liabilities held for trading 4,759,250.98 755,634.43
Notes payable 1,659,215,210.65 1,635,906,989.22
Accounts payable 1,044,610,610.21 943,905,580.91
Receipts in advance
Contract liabilities 118,380,947.47 292,977,730.74
Employee benefits payable 361,917,343.05 573,010,571.46
Taxes payable 302,213,706.06 337,702,273.73
Other payables 3,650,990,302.39 3,680,334,360.88
In which: Interests payable
7 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Dividends payable 11,892,804.66 12,252,074.84
Liabilities held-for-sale
Non-current liabilities due within one year 65,000,820.80 63,077,260.98
Other current liabilities 88,863,541.97 101,276,714.35
Total current liabilities 9,395,021,446.59 9,754,997,731.76
Non-current liabilities:
Long-term loans 3,666,476,993.70 3,230,844,042.88
Bonds payable
Lease liabilities 20,171,911.31 23,482,486.07
Long-term payables
Long-term payroll payable
Estimated liabilities
Deferred income 441,393,354.98 384,537,267.55
Deferred income tax liabilities 232,294,155.75 231,164,425.48
Other non-current liabilities 90,000,000.00 84,000,000.00
Total non-current liabilities 4,450,336,415.73 3,954,028,221.98
Total liabilities 13,845,357,862.33 13,709,025,953.74
Owner's equity (or shareholder's equity):
Paid-in capital 1,929,189,374.00 1,929,189,374.00
Other equity instruments
In which: Preferred shares
Perpetual debts
Capital reserve 2,541,441,353.22 2,343,693,215.99
Less: Treasury shares 717,135,581.08 347,176,561.29
Other comprehensive income -42,580,905.41 4,704,473.53
Special reserve
Surplus reserve 734,766,581.50 734,766,581.50
Undistributed profits 8,919,389,509.85 8,456,643,326.82
Total owner's equity (or shareholder's equity)
13,365,070,332.08 13,121,820,410.55
attributable to the parent company
Minority shareholder's equity 8,982,622,820.65 8,898,407,287.12
Total owner's equity (or shareholder's equity) 22,347,693,152.74 22,020,227,697.67
Total liabilities and owner's equity (or
36,193,051,015.06 35,729,253,651.41
shareholder's equity)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
8 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Consolidated Income Statement
From January to March, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First quarter (January to First quarter (January to
Item
March) for 2023 March) for 2022
I. Total revenues 4,559,049,786.82 4,657,343,538.89
In which: Operating revenues 4,559,049,786.82 4,657,343,538.89
II. Total operating costs 3,563,214,097.57 3,650,160,694.91
In which: Operating costs 1,713,465,807.02 1,611,006,712.60
Operating tax and surcharges 54,610,788.80 52,198,225.41
Selling expenses 1,220,569,090.59 1,413,289,256.99
Administrative expenses 209,257,340.10 252,854,561.35
R&D expenses 381,172,496.49 351,331,244.23
Financial expenses -15,861,425.43 -30,519,305.67
In which: Interest expenses 33,036,361.57 29,854,923.66
Interest income 68,217,553.45 68,468,649.16
Add: Other income 54,191,288.49 59,138,624.91
Income from investments (loss is
39,625,949.95 29,176,808.52
indicated by“-”)
In which: Income from investments
11,470,389.65 15,204,632.53
in associates and joint ventures
Gains from derecognition of
financial assets at amortized cost
Gains from net exposure hedges
(loss is indicated by“-”)
Gains from changes in fair values
-27,478,190.74 -54,151,999.18
(loss is indicated by“-”)
Losses of credit impairment (loss is
-15,459,174.59 217,773.10
indicated by“-”)
Assets impairment loss (loss is
1,837,691.27 -5,309,013.21
indicated by“-”)
Gains from disposal of assets (loss
-370,357.71
is indicated by“-”)
III. Operating profit (loss is indicated
1,048,553,253.63 1,035,884,680.41
by“-”)
Add: Non-operating income 876,580.36 2,321,933.96
Less: Non-operating expenses 3,698,829.74 2,084,578.34
IV. Total profit (loss is indicated by“-”) 1,045,731,004.25 1,036,122,036.03
Less: Income tax expenses 167,212,968.94 173,764,775.30
V. Net profit (loss is indicated by“-”) 878,518,035.31 862,357,260.73
(I) Classified by business continuity
1. Net profit from ongoing operation
878,518,035.31 862,357,260.73
(loss is indicated by“-”)
2. Net profit from discontinuing
operation (loss is indicated by“-”)
(II) Classified by ownership
1.Net profit attributable to
shareholders of the parent company 462,746,183.03 460,537,813.53
(loss is indicated by“-”)
2.Profit and loss of minority
415,771,852.27 401,819,447.20
shareholders (loss is indicated by“-”)
9 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
VI. Other comprehensive income, net of
-83,671,573.75 -106,847,774.60
tax
(I) Other comprehensive income
attributable to owners of the parent -47,285,378.94 -92,885,997.05
company, net of tax
1. Other comprehensive income that
cannot be reclassified into profit or -20,803,179.78 -75,513,312.70
loss
(1) Changes from remeasurement of
defined benefit plans
(2) Other comprehensive income
that cannot be reclassified into profit or
loss under the equity method
(3) Changes in fair value of
-20,803,179.78 -75,513,312.70
investments in other equity instruments
(4) Changes in fair value of the
enterprise's own credit risks
2. Other comprehensive income that
-26,482,199.17 -17,372,684.35
will be reclassified into profit or loss
(1) Other comprehensive income
that can be reclassified into profit or loss
under the equity method
(2) Changes in fair value of other
debt investments
(3) Amount of financial assets
reclassified into other comprehensive
income
(4) Provision for credit impairment
of other debt investments
(5) Reserve for cash flow hedges
(6) Exchange translation differences
on financial statements denominated in -26,482,199.17 -17,372,684.35
foreign currencies
(7) Others
(II) Other comprehensive income
attributable to minority shareholders, -36,386,194.81 -13,961,777.55
net of tax
VII. Total comprehensive income 794,846,461.55 755,509,486.13
(I) Total comprehensive income
attributable to owners of the parent 415,460,804.09 367,651,816.48
company
(II) Total comprehensive income
379,385,657.46 387,857,669.65
attributable to minority shareholders
VIII. Earnings per share:
(I) Basic earnings per share (RMB/share) 0.2404 0.2411
(II) Diluted earnings per share
0.2398 0.2410
(RMB/share)
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
10 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
Consolidated Cash Flow Statement
From January to March, 2023
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
First quarter First quarter
Item (January to (January to
March) for 2023 March) for 2022
I. Cash flow from operating activities:
Cash received from sales of goods and rendering of services 4,361,096,155.32 4,614,758,574.74
Tax refunds received 40,439,680.21 32,240,811.32
Other cash received related to operating activities 202,829,024.01 172,771,264.97
Subtotal of cash inflow from operating activities 4,604,364,859.54 4,819,770,651.03
Cash paid for goods and services 1,563,463,357.75 1,165,780,579.10
Cash paid to and on behalf of employees 820,337,183.05 758,821,581.15
Payments of all types of taxes 541,191,286.96 420,627,138.84
Other cash paid related to operating activities 1,431,288,281.07 1,602,636,874.96
Subtotal of cash outflow in operating activities 4,356,280,108.83 3,947,866,174.05
Net cash flow from operating activities 248,084,750.71 871,904,476.98
II. Cash flow from investing activities:
Cash received from disposal of investment 70,031,257.75 216,970,980.42
Cash received from investment income 26,244,584.66 6,832,308.83
Net cash received from disposal of fixed assets, intangible
88,664.00 346,152.00
assets and other long-term assets
Net cash received from disposal of subsidiaries and other
business units
Other cash received related to investing activities 297,605,105.05 7,668,394.07
Subtotal of cash inflow from investing activities 393,969,611.46 231,817,835.32
Cash paid for purchase and construction of fixed assets,
244,675,030.69 277,850,093.60
intangible assets and other long-term assets
Cash paid for investment 6,183,753.84 30,338,557.45
Net cash paid for acquisition of subsidiaries and other
12,461,951.59
business units
Other cash paid related to investing activities 202,160,184.88 1,537,021.94
Subtotal of cash outflow in investing activities 465,480,921.00 309,725,672.99
Net cash flow from investing activities -71,511,309.54 -77,907,837.67
III. Cash flow from financing activities:
Cash received from capital contribution 53,414,701.36
In which: Cash received from investment by minority
interests of subsidiaries
Cash received from borrowings 1,249,525,870.74 1,923,486,837.26
Other cash received related to financing activities 130,847,366.53
Subtotal of cash inflow from financing activities 1,249,525,870.74 2,107,748,905.15
Cash repayments of amounts borrowed 715,074,985.04 1,776,859,803.19
Cash payments for interest expenses and distribution of
41,156,153.68 19,177,786.10
dividends or profits
In which: Dividends and profit paid minority interests of
359,270.18
subsidiaries
Other cash payments related to financing activities 611,939,083.83 248,996,762.52
Subtotal of cash outflow in financing activities 1,368,170,222.55 2,045,034,351.81
Net cash flow from financing activities -118,644,351.81 62,714,553.34
IV. Effect of exchange rate fluctuations on cash and cash
-47,773,910.21 -12,259,201.98
equivalents
V. Net increase in cash and cash equivalents 10,155,179.14 844,451,990.66
Add: Opening balance of cash and cash equivalents 14,178,465,686.40 11,697,518,141.18
11 / 12
Joincare Pharmaceutical Group Industry Co., Ltd. 2023 First Quarterly Report
VI. Closing balance of cash and cash equivalents 14,188,620,865.54 12,541,970,131.84
Person-in-charge of the Person-in-charge of the Person-in-charge of the
Company: Zhu Baoguo Company's accounting work: accounting department:
Qiu Qingfeng Qiu Qingfeng
Implementation of new accounting standards or interpretations of standards, for the first time from 2023
involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
24 April, 2023
12 / 12
